Security
Vivos Therapeutics, Inc. Common Stock · VVOS
VVOSNASDAQCommon stockCurrentCIK 1716166Updated Nov 3, 2026
Name history
Vivos BioTechnologies, Inc. · through Sep 29, 2017
VVOS price & chart
Loading TradingView…
NASDAQ:VVOS on TradingView ↗In the news
No coverage from other publishers is available.
Recent filings
DEFA14A filing
DEF 14A filing
4 filing
PRER14A filing
Other Events
Items 8.01, 9.01
Show 5 more recent filings
PRE 14A filing
Entry into a Material Definitive Agreement · Completion of Acquisition or Disposition of Assets · Unregistered Sales of Equity Securities · Material Modification to Rights of Security Holders · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Regulation FD Disclosure · Other Events
Items 1.01, 2.01, 3.02, 3.03, 5.03, 7.01, 8.01, 9.01
Entry into a Material Definitive Agreement · Regulation FD Disclosure · Other Events
Items 1.01, 7.01, 8.01, 9.01
Changes in Registrant's Certifying Accountant
Items 4.01, 9.01
4 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 25,644,000Source | 15,347,000Source | 24,144,000Source | 26,033,000Source | 15,842,000Source | 25,043,000Source | 11,282,000Source | 11,804,000Source | 25,152,000Source | 15,284,000Source | 10,730,000Source | 13,720,000Source |
| Property, Plant and Equipment, NetUSD | 5,642,000Source | 3,317,000Source | 3,640,000Source | 5,129,000Source | 3,259,000Source | 3,526,000Source | 3,308,000Source | 3,332,000Source | 3,757,000Source | 3,350,000Source | 3,314,000Source | 3,082,000Source |
| GoodwillUSD | 8,450,000Source | 2,843,000Source | 8,572,000Source | 8,450,000Source | 2,843,000Source | 8,572,000Source | 2,843,000Source | 2,843,000Source | 8,572,000Source | 2,843,000Source | 2,843,000Source | 2,843,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 2,172,000Source | 383,000Source | 3,638,000Source | 2,225,000Source | 395,000Source | 3,839,000Source | 358,000Source | 408,000Source | 4,045,000Source | 370,000Source | 420,000Source | 302,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 3,087,000Source | 6,311,000Source | 1,774,000Source | 4,402,000Source | 6,903,000Source | 2,110,000Source | 2,342,000Source | 2,611,000Source | 2,029,000Source | 6,260,000Source | 1,643,000Source | 3,519,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 2,134,000Source | 454,000Source | 1,438,000Source | 1,633,000Source | 395,000Source | 1,769,000Source | 718,000Source | 525,000Source | 1,581,000Source | 430,000Source | 202,000Source | 457,000Source |
| Assets, CurrentUSD | 5,786,000Source | 7,399,000Source | 4,213,000Source | 6,730,000Source | 7,852,000Source | 4,819,000Source | 3,607,000Source | 3,611,000Source | 4,384,000Source | 7,473,000Source | 2,461,000Source | 5,424,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 565,000Source | 634,000Source | 1,001,000Source | 695,000Source | 554,000Source | 940,000Source | 547,000Source | 475,000Source | 774,000Source | 783,000Source | 616,000Source | 1,448,000Source |
| Operating Lease, Right-of-Use AssetUSD | 3,383,000Source | 1,129,000Source | 3,809,000Source | 3,244,000Source | 1,217,000Source | 4,033,000Source | 951,000Source | 1,302,000Source | 4,166,000Source | 1,032,000Source | 1,385,000Source | 1,695,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 23,112,000Source | 7,682,000Source | 28,130,000Source | 21,450,000Source | 9,495,000Source | 26,310,000Source | 6,875,000Source | 11,222,000Source | 26,702,000Source | 7,330,000Source | 10,319,000Source | 8,919,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 1,000Source | — | 1,000Source | — | — | 1,000Source | — | — | 1,000Source | — | — | 2,000Source |
| Additional Paid in CapitalUSD | 120,995,000Source | 109,025,000Source | 133,599,000Source | 117,647,000Source | 105,091,000Source | 131,900,000Source | 112,458,000Source | 97,396,000Source | 123,866,000Source | 112,141,000Source | 93,462,000Source | 84,267,000Source |
| Retained Earnings (Accumulated Deficit)USD | -118,464,000Source | -101,360,000Source | -138,520,000Source | -113,064,000Source | -98,744,000Source | -133,039,000Source | -108,051,000Source | -96,814,000Source | -125,357,000Source | -104,187,000Source | -93,051,000Source | -79,468,000Source |
| Stockholders' Equity Attributable to ParentUSD | 2,532,000Source | 7,665,000Source | -3,815,000Source | 4,583,000Source | 6,347,000Source | -1,138,000Source | 4,407,000Source | 582,000Source | -1,490,000Source | 7,954,000Source | 411,000Source | 4,801,000Source |
| Liabilities and EquityUSD | 25,644,000Source | 15,347,000Source | 24,144,000Source | 26,033,000Source | 15,842,000Source | 25,043,000Source | 11,282,000Source | 11,804,000Source | 25,152,000Source | 15,284,000Source | 10,730,000Source | 13,720,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 7,437,000Source | 5,126,000Source | 20,389,000Source | 6,426,000Source | 6,643,000Source | 17,937,000Source | 4,701,000Source | 8,070,000Source | 18,076,000Source | 4,978,000Source | 7,289,000Source | 6,813,000Source |
| Operating Lease, Liability, CurrentUSD | 734,000Source | 485,000Source | 790,000Source | 654,000Source | 484,000Source | 744,000Source | 467,000Source | 483,000Source | 672,000Source | 477,000Source | 474,000Source | 419,000Source |
| Accounts Payable, CurrentUSD | 2,103,000Source | 1,075,000Source | 2,946,000Source | 1,763,000Source | 2,028,000Source | 1,996,000Source | 1,206,000Source | 2,499,000Source | 1,679,000Source | 1,098,000Source | 2,145,000Source | 1,411,000Source |
| Operating Lease, Liability, NoncurrentUSD | 2,866,000Source | 1,158,000Source | 3,438,000Source | 2,814,000Source | 1,280,000Source | 3,653,000Source | 932,000Source | 1,399,000Source | 3,840,000Source | 1,035,000Source | 1,521,000Source | 1,994,000Source |
| Other Liabilities, NoncurrentUSD | 1,400,000Source | — | 950,000Source | 1,400,000Source | — | 1,300,000Source | — | — | 1,300,000Source | — | — | — |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | — | — | -171,000Source | — | — | -129,000Source | — | — | -60,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 2,682,000Source | 2,054,000Source | 7,042,000Source | 2,302,000Source | 2,185,000Source | 6,113,000Source | 1,784,000Source | 2,466,000Source | 5,988,000Source | 2,234,000Source | 2,334,000Source | 1,912,000Source |
| Deferred Revenue, CurrentUSD | 500,000Source | 1,300,000Source | 600,000Source | 500,000Source | 1,800,000Source | 500,000Source | 600,000Source | 2,400,000Source | 500,000Source | 900,000Source | 2,100,000Source | 2,900,000Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 1,114,000Source | — | — | — |
| Long-term Debt, Excluding Current Maturities | — | — | — | — | — | — | — | — | —Source | — | — | — |
| Long-term Debt, Current MaturitiesUSD | 339,000Source | — | 7,772,000Source | 157,000Source | — | 7,299,000Source | — | — | 8,353,000Source | — | — | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 8,379,000Source | — | 366,000Source | 7,760,000Source | — | 418,000Source | — | — | 469,000Source | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | -5,523,000Source | -5,013,000Source | -7,751,000Source | -3,864,000Source | -21,230,000Source | — | — | — |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | 510,000Source | — | 454,000Source | 177,000Source | 1,309,000Source | 581,000Source | 621,000Source | 669,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 151,000Source | 317,000Source | 661,000Source | 762,000Source | 1,106,000Source | 2,396,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 188,000Source | 288,000Source | 217,000Source | 228,000Source | -255,000Source | -746,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 318,000Source | 109,000Source | 524,000Source | -1,048,000Source | 734,000Source | 491,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -6,010,000Source | -3,796,000Source | -15,263,000Source | -12,691,000Source | -11,946,000Source | -19,587,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -18,000Source | -122,000Source | -7,526,000Source | -568,000Source | -853,000Source | -924,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 18,000Source | 122,000Source | 2,341,000Source | 568,000Source | 803,000Source | 924,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 6,109,000Source | — | 18,558,000Source | 17,876,000Source | 10,923,000Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 81,000Source | -3,918,000Source | -4,231,000Source | 4,617,000Source | -1,876,000Source | -20,511,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 340,000Source | — | — | 9,000Source | — | 2,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 100,000Source | 100,000Source | 100,000Source | 300,000Source | 200,000Source | 300,000Source | 700,000Source | 800,000Source | — | 700,000Source |
| Amortization of Intangible AssetsUSD | — | — | 100,000Source | 100,000Source | 200,000Source | 100,000Source | 200,000Source | 100,000Source | 600,000Source | 100,000Source | 100,000Source | 100,000Source |
| DepreciationUSD | — | — | 400,000Source | 100,000Source | 300,000Source | 300,000Source | 300,000Source | 200,000Source | 700,000Source | 600,000Source | 700,000Source | 600,000Source |
| Derivative, Gain (Loss) on Derivative, NetUSD | — | — | — | — | — | — | — | — | — | — | 10,231,000Source | — |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | — | — | — | — | — | — | — | — | — | — | — | -36,000Source |
| General and Administrative ExpenseUSD | — | — | 7,884,000Source | 4,487,000Source | 7,113,000Source | 6,409,000Source | 8,971,000Source | 4,892,000Source | 27,727,000Source | 17,878,000Source | 22,479,000Source | 29,041,000Source |
| GoodwillUSD | — | — | 8,450,000Source | 2,843,000Source | 8,572,000Source | 8,450,000Source | 8,572,000Source | 2,843,000Source | 8,572,000Source | 2,843,000Source | 2,843,000Source | 2,843,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -5,400,000Source | -2,616,000Source | -5,481,000Source | -5,013,000Source | -7,682,000Source | -3,864,000Source | -21,170,000Source | -11,136,000Source | -13,583,000Source | -23,845,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | — | — | -42,000Source | — | -69,000Source | — | -60,000Source | — | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -5,400,000Source | -2,616,000Source | -5,481,000Source | -5,013,000Source | -7,682,000Source | -3,864,000Source | -21,230,000Source | -11,136,000Source | -13,583,000Source | -23,845,000Source |
| Operating ExpensesUSD | — | — | 8,671,000Source | 4,979,000Source | 7,778,000Source | 6,975,000Source | 9,674,000Source | 5,427,000Source | 30,436,000Source | 20,190,000Source | 25,567,000Source | 35,050,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -679,000Source | -18,000Source | -1,050,000Source | -163,000Source | -1,167,000Source | -4,000Source | -1,481,000Source | -110,000Source | -212,000Source | -190,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 342,000Source | — | 5,576,000Source | 7,796,000Source | — | — |
| Proceeds from Issuance of Long-term DebtUSD | — | — | — | — | — | — | 1,400,000Source | — | 10,673,000Source | — | — | — |
| Debt Securities, Available-for-sale, Realized Gain (Loss) | — | — | — | — | —Source | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 6,783,000Source | 3,860,000Source | 5,153,000Source | 3,820,000Source | 5,141,000Source | 3,016,000Source | 17,443,000Source | 15,031,000Source | 13,801,000Source | 16,024,000Source |
| Cost of RevenueUSD | — | — | — | — | — | — | — | — | 6,901,000Source | 6,012,000Source | 200,000Source | 100,000Source |
| Operating Income (Loss)USD | — | — | -4,734,000Source | -2,645,000Source | -4,825,000Source | -4,865,000Source | -6,615,000Source | -3,918,000Source | -19,894,000Source | -11,171,000Source | -17,296,000Source | -25,031,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -679,000Source | -18,000Source | -1,050,000Source | -163,000Source | -1,167,000Source | -4,000Source | -1,481,000Source | -110,000Source | -212,000Source | -190,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -5,400,000Source | -2,616,000Source | -5,523,000Source | -5,013,000Source | -7,751,000Source | -3,864,000Source | -21,230,000Source | -11,136,000Source | -13,583,000Source | -23,845,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | — | — | -42,000Source | — | -69,000Source | — | -60,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -5,400,000Source | -2,616,000Source | -5,481,000Source | -5,013,000Source | -7,682,000Source | -3,864,000Source | -21,170,000Source | -11,136,000Source | -13,583,000Source | -23,845,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.49Source | -0.4Source | -0.31Source | -0.55Source | -0.52Source | -0.45Source | -2.07Source | -2.22Source | -11.14Source | -1.04Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.49Source | -0.4Source | -0.31Source | -0.55Source | -0.52Source | -0.45Source | -2.07Source | -2.22Source | -11.14Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 10,963,590Source | 6,615,320Source | 17,681,945Source | 9,087,202Source | 14,634,115Source | 8,595,288Source | 10,273,881Source | 5,019,886Source | 1,219,381Source | 23,012,119,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 10,963,590Source | 6,615,320Source | 17,681,945Source | 9,087,202Source | 14,634,115Source | 8,595,288Source | 10,273,881Source | 5,019,886Source | 1,219,381Source | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | 100,000Source | 100,000Source | 200,000Source | 100,000Source | 200,000Source | 100,000Source | 600,000Source | 100,000Source | 100,000Source | 100,000Source |
| Cost of Goods and Service, Excluding Depreciation, Depletion, and AmortizationUSD | — | — | 2,846,000Source | 1,526,000Source | 2,200,000Source | 1,710,000Source | 2,082,000Source | 1,507,000Source | 6,901,000Source | 6,012,000Source | 5,530,000Source | 6,005,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | 384,000Source | 146,000Source | 510,000Source | 306,000Source | 454,000Source | 177,000Source | 1,309,000Source | 581,000Source | 621,000Source | 669,000Source |
| General and Administrative ExpenseUSD | — | — | 7,884,000Source | 4,487,000Source | 7,113,000Source | 6,409,000Source | 8,971,000Source | 4,892,000Source | 27,727,000Source | 17,878,000Source | 22,479,000Source | 29,041,000Source |
| Gross ProfitUSD | — | — | 3,937,000Source | 2,334,000Source | 2,953,000Source | 2,110,000Source | 3,059,000Source | 1,509,000Source | 10,542,000Source | 9,019,000Source | 8,271,000Source | 10,019,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -21,230,000Source | -11,194,000Source | -13,626,000Source | -23,945,000Source |
| Interest ExpenseUSD | — | — | 500,000Source | — | 1,100,000Source | — | 1,100,000Source | — | 1,400,000Source | — | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -5,400,000Source | -2,616,000Source | -5,481,000Source | -5,013,000Source | -7,682,000Source | -3,864,000Source | -21,230,000Source | -11,136,000Source | -13,583,000Source | -23,845,000Source |
| Operating ExpensesUSD | — | — | 8,671,000Source | 4,979,000Source | 7,778,000Source | 6,975,000Source | 9,674,000Source | 5,427,000Source | 30,436,000Source | 20,190,000Source | 25,567,000Source | 35,050,000Source |
| Other IncomeUSD | — | — | 13,000Source | 47,000Source | 352,000Source | 15,000Source | 31,000Source | 58,000Source | 145,000Source | 145,000Source | 147,000Source | — |
| Research and Development ExpenseUSD | — | — | — | — | — | — | — | — | 100,000Source | 100,000Source | 100,000Source | 200,000Source |
| Selling and Marketing ExpenseUSD | — | — | 403,000Source | 346,000Source | 155,000Source | 260,000Source | 249,000Source | 358,000Source | 1,400,000Source | 1,731,000Source | 2,467,000Source | 5,340,000Source |
Offerings
Registration 333-293492
Registration 333-278564
Filing attachments
ex99-1.htm · 8-K · 2026-10-21
Exhibit 99.1 Vivos Therapeutics Reports Nasdaq Confirmation of Compliance with Continued Listing Shareholders’ Equity Standard LITTLETON, Colo., October 21, 2026 - Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (Nasdaq: VVOS), a medical device and healthcare services company focused on developing and commercializing diagnostic and treatment methods for patients with obstructive sleep apnea (“OSA”) and other breathing and sleep-related health conditions, today announced receipt of a letter…
Read attachment ↗ex99-1.htm · 8-K · 2026-10-19
Exhibit 99.1 Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel Transaction Expected to Add More Than $10 Million to Stockholders’ Equity as Vivos Forms Strategic Alliances Offering Potential New Revenue and Profit Opportunities LITTLETON, Colo., October 19, 2026 - Vivos Therapeutics, Inc. (Nasdaq: VVOS) (“Vivos” or the “Company”) today announced that i…
Read attachment ↗ex99-1.htm · 8-K · 2026-10-15
Exhibit 99.1 Vivos Therapeutics Agrees to Acquire Minority Stake in SOD Sciences and 50% Interest in Proprietary Pseudohypoxia Test Transaction Expected to Increase Stockholders’ Equity; Opens Potential Collaboration Opportunities From New Strategic Alliances LITTLETON, Colo., October 15, 2026 - Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (Nasdaq: VVOS), a medical device and healthcare services company focused on developing and commercializing diagnostic and treatment methods for pati…
Read attachment ↗ex99-1.htm · 8-K · 2026-08-21
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Vivos Therapeutics Opens New Sleep Testing and Treatment Facility in Nevada to Meet Rapidly Growing Patient Demand for Sleep Apnea Testing and Treatment New Location Expected to More Than Double Annual Revenue Production Capacity to Over $10 Million Official Grand Opening Slated for August 27 in Henderson, Nevada With Prominent Industry Opinion Leaders, Sleep Physicians, Dentists Among Scheduled Attendees LITTLETON, Colo., August 20, 2026 - Vivos…
Read attachment ↗ex99-1.htm · 8-K · 2026-08-11
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Vivos Therapeutics Announces Issuance of New US Patent Broadening Protection for Its Vivos CARE Oral Medical Device Technology Continuation Patent Secures Broader, Design Independent Claims, Building on the Company’s 2024 Foundational Patent for Its Vibrational Oral Appliance Platform LITTLETON, Colo., Aug. 05, 2026 (GLOBE NEWSWIRE) - Vivos Therapeutics, Inc. (“Vivos” or “the Company”) (NASDAQ: VVOS), a leading medical device and healthcare servic…
Read attachment ↗ex4-1.htm · 8-K · 2026-07-07
EX-4.1 2 ex4-1.htm EX-4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE …
Read attachment ↗